The diagnostic accuracy of faecal calprotectin and small bowel capsule endoscopy and their correlation in suspected isolated small bowel Crohn’s disease

Hale, Melissa F; Drew, K; McAlindon, Mark E.; Sidhu, Reena

doi:10.1097/meg.0000000000000696

Cited by 20 publications

(30 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most studies reported higher FC concentrations in CD patients than in those with normal small bowel findings or other disease conditions, but not always a significant association with CE findings …”

Section: Resultsmentioning

confidence: 91%

“…Considerable variability was observed among different cohorts of patients using the same FC cutoff (50 μg/g), with values of the sensitivity, specificity, PPV, and NPV being, respectively, 59–88.9%, 23–71%, 14.3–56%, and 83–94.1% …”

Section: Resultsmentioning

confidence: 99%

“…All the reported values of the sensitivity and specificity, according to different FC levels, are summarized in Table …”

Section: Resultsmentioning

confidence: 99%

“…23 Considerable variability was observed among different cohorts of patients using the same FC cutoff (50 μg/g), with values of the sensitivity, specificity, PPV, and NPV being, respectively, 59-88.9%, 23-71%, 14.3-56%, and 83-94.1%. 24,25 Most studies reported higher FC concentrations in CD patients than in those with normal small bowel findings or other disease conditions, but not always a significant association with CE findings. 24,26 Higher threshold values (> 100 and > 95 μg/g) showed better sensitivity, specificity, NPV, and PPV in two other trials (75%, 67%, 79%, and 62% 25 and 77%, 60%, 84%, and 50% 27 ).…”

Section: Resultsmentioning

confidence: 99%

“…24,25 Most studies reported higher FC concentrations in CD patients than in those with normal small bowel findings or other disease conditions, but not always a significant association with CE findings. 24,26 Higher threshold values (> 100 and > 95 μg/g) showed better sensitivity, specificity, NPV, and PPV in two other trials (75%, 67%, 79%, and 62% 25 and 77%, 60%, 84%, and 50% 27 ).…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

Is fecal calprotectin an accurate marker in the management of Crohn's disease?

Vernia

Ruscio

Stefanelli

et al. 2019

J of Gastro and Hepatol

View full text Add to dashboard Cite

Although lacking validated cutoff values, fecal calprotectin (FC), besides C‐reactive protein, is considered the standard test for assessing disease activity in Crohn's disease (CD). The aim of the present review is to provide a general overview of the literature addressing the role of FC in the clinical and endoscopic assessment of disease activity in CD, seeking correlations with capsule endoscopy, response to therapy, prediction of relapse, and postoperative recurrence. A systematic search of the literature up to September 2019 was performed using Medline, Embase, and the Cochrane Library. Only papers written in English concerning FC in adult patients affected by CD were included. Pediatric studies, in vitro studies, animal studies, studies on blood/serum samples, and studies analyzing FC in ulcerative colitis or in both CD and ulcerative colitis were excluded. Out of 713 citations, 65 eligible studies were identified. FC showed high accuracy in the assessment of intestinal inflammation and response to therapy, in particular in colonic disease, thus proving a good surrogate marker for these aims. FC is useful in identifying patients at high risk for endoscopic relapse or postoperative recurrence, for optimizing or downstage therapy. Unfortunately, FC performs less well in small bowel CD. FC is an effective fecal marker in the management of CD patients, optimizing the use of endoscopic procedures. Owing to its diagnostic accuracy, FC may represent a cornerstone of the “treat‐to‐target” management strategy of CD patients.

show abstract

Section: Resultsmentioning

confidence: 91%

Section: Resultsmentioning

confidence: 99%

“…All the reported values of the sensitivity and specificity, according to different FC levels, are summarized in Table …”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Is fecal calprotectin an accurate marker in the management of Crohn's disease?

Vernia

Ruscio

Stefanelli

et al. 2019

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

The utility of capsule endoscopy in the phenotype of Crohn’s disease. Data from England 2016–2021

Oka,

Vibhishanan,

Chetcuti Zammit

et al. 2024

Arab Journal of Gastroenterology

View full text Add to dashboard Cite

Capsule Endoscopy in Inflammatory Bowel Disease: A Systematic Review

Pal,

Banerjee,

Gupta

et al. 2023

Journal of Digestive Endoscopy

View full text Add to dashboard Cite

The role of video capsule endoscopy (VCE) in inflammatory bowel disease (IBD) has evolved from small bowel to a panenteric evaluation tool over the past two decades. We systematically reviewed the techniques, applications, outcomes, and complications of VCE in IBD. A systematic literature search was performed using PubMed, Embase, and Medline. All relevant original articles involving VCE in IBD were included from 2003 to July 2022. After screening 3,089 citations, finally 201 references were included. The diagnostic yield of VCE in suspected Crohn's disease (CD) was highly variable (6–80%) with excellent sensitivity (77–93%) and specificity (80–89%). The diagnostic yield in known CD was 52 to 88.3% leading to a change in management (26–75%) and disease reclassification with variable retention rates. VCE was superior to small bowel series, computed tomography (CT) and could be better than magnetic resonance enterography (MRE), especially for proximal and superficial lesions. Colon or panenteric VCE has strong correlation to ileo-colonoscopy (IC) and combined magnetic resonance imaging and IC, respectively. The VCE retention rate in CD is higher in known CD which significantly decreases after the negative patency capsule test or CT/MRE. VCE can identify lesions beyond the reach of IC in postoperative CD. Colon Capsule Endoscopy is a noninvasive monitoring tool in ulcerative colitis (UC) having a strong correlation with IC and may uncover small bowel involvement. VCE is specifically useful in IBD-unclassified (IBD-U) which can lead to the diagnosis of CD in 16.7 to 61.5%. Various scoring systems have been established and validated for small bowel CD (Lewis score and capsule endoscopy CD activity index—CECDAI), UC (capsule scoring of UC: Capsule Scoring of Ulcerative Colitis), panenteric evaluation (Capsule Endoscopy Crohn's Disease Activity Index, Elaikim score), and flare prediction (APEX score). Technological advances include double head, three-dimensional reconstruction, sampling system, panoramic view (344 and 360 degree lateral), and panenteric capsule. Artificial intelligence and software like TOP100 and Quickview can help reduce capsule reading time with excellent sensitivity and specificity. VCE in IBD has widespread application in suspected and known small bowel CD, monitoring of UC, postoperative CD, IBD-U, and for panenteric evaluation. Patency capsule testing helps to reduce retention rates significantly. Artificial intelligence and technical advances can help evolve this novel technology.

show abstract

The diagnostic accuracy of faecal calprotectin and small bowel capsule endoscopy and their correlation in suspected isolated small bowel Crohn’s disease

Abstract: FC performs modestly as a screening test to exclude small bowel inflammation. However, we recommend interpretation within the overall clinical context to avoid overlooking the infrequent patient with small bowel inflammation and a negative FC.

Cited by 20 publications

References 34 publications

Is fecal calprotectin an accurate marker in the management of Crohn's disease?

Is fecal calprotectin an accurate marker in the management of Crohn's disease?

The utility of capsule endoscopy in the phenotype of Crohn’s disease. Data from England 2016–2021

Capsule Endoscopy in Inflammatory Bowel Disease: A Systematic Review

Contact Info

Product

Resources

About